EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The monoclonal antibody anti-CD20 for the treatment of patients with low grade non Hodgkins lymphoma



The monoclonal antibody anti-CD20 for the treatment of patients with low grade non Hodgkins lymphoma



Annals of Hematology 77(SUPPL 2): S26




(PDF emailed within 1 workday: $29.90)

Accession: 033871728

Download citation: RISBibTeXText



Related references

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 38(5 SUPPL ): 251P, 1997

A phase II study of fludarabine phosphate and mitoxantrone followed by anti-CD20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low-grade non-Hodgkins lymphoma Interim results. Blood 102(11): 412a, November 16, 2003

Multicenter randomized phase II study of the monoclonal anti-CD20 antibody Rituximab in patients with intermediate/high grade non-Hodgkins lymphoma. Annals of Hematology 77(SUPPL 2): S180, 1998

Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkins lymphoma The German experience. Blood 96(11 Part 1): 729a, November 16, 2000

Monoclonal anti-CD20 antibody rituximab is safe and efficient in patients with CD20-positive Hodgkins lymphoma. Onkologie 23(Sonderheft 7): 147, October, 2000

A phase II study of mitoxantrone and fludarabine followed by anti-CD20 monoclonal in the treatment of patients with previously untreated low grade non-Hodgkins lymphoma. Blood 96(11 Part 1): 732a, November 16, 2000

IDEC-C2B8 chimeric anti-CD20 antibody Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular non-Hodgkins lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 17(1): 268-276, 1999

The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma cell lines. Blood 88(10 SUPPL 1 PART 1-2): 637A, 1996

Internal radiotherapy - II. Treatment of non-Hodgkins lymphoma with Y-90-labeled anti-CD20 monoclonal antibody. Radioisotopes 56(4): 197-202, 2007

Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkins lymphoma using the monoclonal anti-CD20 antibody rituximab Evaluation of safety and response. Blood 94(10 SUPPL 1 PART 2): 270b, Nov 15, 1999

Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies. Annals of Hematology 77(SUPPL 2): S148, 1998

Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody. American Journal of Clinical Oncology 26(4): 408-410, 2003

Anti-CD20 monoclonal antibody in gastric extranodal marginal zone non-Hodgkins lymphoma patients Clinical and biological results. Blood 102(11): 140a, November 16, 2003

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 8(10): 544-549, 2002